Prognostic relevance of MAPK expression in glioblastoma multiforme

  • Authors:
    • Christian Mawrin
    • Sabine Diete
    • Tim Treuheit
    • Siegfried Kropf
    • Christian K. Vorwerk
    • Carsten Boltze
    • Elmar Kirches
    • Raimund Firsching
    • Knut Dietzmann
  • View Affiliations

  • Published online on: September 1, 2003     https://doi.org/10.3892/ijo.23.3.641
  • Pages: 641-648
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of this study was to determine the immunoexpression pattern of the mitogen-activated protein kinase (MAPK), and related signalling proteins [protein kinase C (PKC), phospholipase Cγ (PLCγ)], in glioblastoma multi-forme, and to investigate their prognostic value. Paraffin-embedded biopsy samples from 26 patients [13 patients with long-term survival (LTS; N=13; median 28 months, range 13-76 months), and, for comparison, 13 patients with short-term survival (STS; N=13; median 7 months, range 1-12 months)] were investigated for the immunoexpression of MAPK, the activated pMAPK, PKC, PLCγ, EGFR, and PTEN. Additionally, the MIB-1 proliferation index was determined. The immunoexpression pattern were related to clinical data, including analysis of their prognostic value using the Cox-proportional hazard model. No significant differences were found between STS and LTS in terms of age, Karnofsky performance status, and treatment. Whereas EGFR expression did not differ between STS and LTS and does not influence survival, expression of MAPK and activated pMAPK was significantly correlated with survival time. The percentage of pMAPK expressing cells correlated strongly with the percentage of MIB-1 positive cells. Furthermore, survival in patients with tumors expressing PKC or PLCγ was significantly shorter. No differences were found for PTEN expression. Our findings indicate that the MAPK pathway is correlated with proliferation in gliomas, and that patient subgroups exist, in which expression of MAPK-related signalling proteins (PKC, PLCγ) is associated with poorer prognosis. These patient subgroups may benefit from additional chemotherapeutic agents which specifically inhibit these signalling proteins.

Related Articles

Journal Cover

September 2003
Volume 23 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, Kirches E, Firsching R and Dietzmann K: Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 23: 641-648, 2003
APA
Mawrin, C., Diete, S., Treuheit, T., Kropf, S., Vorwerk, C.K., Boltze, C. ... Dietzmann, K. (2003). Prognostic relevance of MAPK expression in glioblastoma multiforme. International Journal of Oncology, 23, 641-648. https://doi.org/10.3892/ijo.23.3.641
MLA
Mawrin, C., Diete, S., Treuheit, T., Kropf, S., Vorwerk, C. K., Boltze, C., Kirches, E., Firsching, R., Dietzmann, K."Prognostic relevance of MAPK expression in glioblastoma multiforme". International Journal of Oncology 23.3 (2003): 641-648.
Chicago
Mawrin, C., Diete, S., Treuheit, T., Kropf, S., Vorwerk, C. K., Boltze, C., Kirches, E., Firsching, R., Dietzmann, K."Prognostic relevance of MAPK expression in glioblastoma multiforme". International Journal of Oncology 23, no. 3 (2003): 641-648. https://doi.org/10.3892/ijo.23.3.641